Benzinga’s Top Ratings Upgrades, Downgrades For January 4, 2023
Upgrades UBS upgraded the previous rating for Trane Technologies PLC (NYSE:TT) from Neutral to Buy. For the third…
William Blair Initiates Coverage On ARS Pharmaceuticals with Outperform Rating
William Blair analyst Tim Lugo initiates coverage on ARS Pharmaceuticals (NASDAQ:SPRY) with a Outperform rating.
Why Avaya Holdings Shares Are Trading Lower By 62%? Here Are 62 Stocks Moving In Friday’s Mid-Day Session
Gainers
Allarity Therapeutics, Inc. (NASDAQ: ALLR) gained 240% to $0.90. Allarity Therapeutics, last month, posted a Q3 loss of $0.68 per share.
Why OpGen Shares Are Trading Higher By 220%? Here Are 64 Stocks Moving In Tuesday’s Mid-Day Session
Gainers
OpGen, Inc. (NASDAQ: OPGN) shares surged 220% to $0.3994 after the company announced topline data from its Unyvero urinary tract infections (UTI) clinical trial.
Benzinga’s Top Ratings Upgrades, Downgrades For December 13, 2022
Upgrades For Equinix Inc (NASDAQ:EQIX), Cowen & Co. upgraded the previous rating of Market Perform to Outperform. In…
SVB Leerink Initiates Coverage On ARS Pharmaceuticals with Outperform Rating, Announces Price Target of $14
SVB Leerink analyst Roanna Ruiz initiates coverage on ARS Pharmaceuticals (NASDAQ:SPRY) with a Outperform rating and announces Price Target of $14.
Russian Court Orders Google to Reinstate Russian Parliament’s Youtube Channel
-Reuters Citing State Duma
ARS Pharmaceuticals Closes Merger With Silverback Therapeutics; neffy NDA Currently Under FDA Review; PDUFA Anticipated Mid-2023 MAA Validated In The European Union Under Review
Over $280 Million in Combined Cash and Securities and at least Three Years Operating Runway to Support Launch and Commercialization of neffy® in the U.S., if Approved
neffy® NDA